Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BL1332 ophthalmic solution, Topical Ocular BL1332 low dose, Ocular BL1332 low dose
BL1332 · 2 trials · 2 indications
Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | EXPERIMENTAL | BL1332 low dose ocular drop used 5x daily |
| Topical Ocular BL1332 high dose | EXPERIMENTAL | BL1332 high dose ocular drop used 5x daily |
| BL1332 ophthalmic vehicle | PLACEBO_COMPARATOR | BL1332 vehicle ocular drop used 5x daily |
| BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) | EXPERIMENTAL | BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) administered as topical ocular drops |
| BL1332 vehicle | PLACEBO_COMPARATOR | BL1332 vehicle administered as topical ocular drops |
| Name | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | DRUG | Administered 5 times a day |
| Topical Ocular BL1332 high dose | DRUG | Administered 5 times a day |
| BL1332 Vehicle ophthalmic vehicle | DRUG | Administered 5 times a day |
| BL1332 ophthalmic solution | DRUG | Both arms taken four times a day for 1 day |
| BL1332 ophthalmic vehicle | DRUG | Both arms taken four times a day for 1 day |
Inclusion Criteria: 1. Male or female 18 to 58 years of age, inclusive. 2. Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion. 3. Provide written informed consent (signed and dated informed consent form \[ICF\]) using the Institutional Review Bo...
BL1332 is an investigational small molecule developed by Bausch + Lomb Corporation (ticker BLCO) as a topical ophthalmic solution. It is being studied for the management of ocular pain, including postoperative ocular pain. BL1332 is not approved and remains in clinical development.
BL1332 is being evaluated for the management of postoperative ocular pain, including pain following photorefractive keratectomy. It is an investigational topical ophthalmic therapy and has not been approved for any indication. Clinical testing is ongoing to assess its potential in this setting.
BL1332 targets TRPV1, an ion channel. TRPV1 is a receptor involved in pain signaling, and BL1332 is designed as a small molecule topical ophthalmic solution directed at this target for ocular pain.
BL1332 is developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is responsible for the clinical development of the topical ophthalmic solution.
BL1332 is in Phase 1 clinical development. A Phase 1 study in healthy volunteers has been conducted, and a Phase 2 study in postoperative ocular pain is planned. BL1332 is investigational and has not been approved by the FDA.
BL1332 has been studied in NCT06978244, a Phase 1 trial assessing safety, tolerability, and pharmacokinetics of ascending concentrations in healthy volunteers. A Phase 2 trial, NCT07412496, is planned to evaluate topical ocular BL1332 for postoperative ocular pain following photorefractive keratectomy.
Yes. BL1332 ophthalmic solution, Topical Ocular BL1332 low dose, and Ocular BL1332 low dose are alternative names for BL1332, the investigational topical ophthalmic small molecule developed by Bausch + Lomb Corporation for ocular pain.